王敬萍,安健,张悟棠,王日军,雷新宇,王仲朝,张晓娟,王慧仙,芦丽芳,李保

• 1:山西省心血管病医院心脏介入中心

摘要(Abstract)：

目的评价普罗布考预防经皮冠状动脉介入治疗(PCI)后再狭窄的作用。方法将准备行PCI的82例稳定型心绞痛患者随机分为普罗布考组(n=42)和普伐他汀组(n=40)。两组患者于术前4周开始服用普罗布考1 000 mg/d或普伐他汀40 mg/d。服药4周后行金属裸支架置入术。术后继续原剂量及方法服用药物至24周。出院后定期随访,术后24周复查冠状动脉造影。结果PCI后随访至24周,两组严重临床事件发生率(死亡、急性心肌梗死、卒中及紧急血运重建术)差异无统计学意义(P>0.05)。复查冠状动脉造影结果显示普罗布考组再狭窄率(22.5%)低于普伐他汀组(36.8%,P<0.05),普罗布考组管腔直径狭窄率及晚期管腔丢失指数(分别为23.25%±10.08%及0.25±0.41)均低于普伐他汀组(分别为34.76%±16.99%及0.42±0.68,P<0.05),纯获得(2.11±1.02 mm)大于普伐他汀组(1.51±0.96 mm,P<0.05)。而两组晚期管腔丢失比较则差异无统计学意义(P>0.05)。结论PCI前4周应用普罗布考降低PCI后再狭窄率的作用优于普伐他汀。

关键词(KeyWords)： 血管成形术,经腔,经皮冠状动脉;冠状动脉再狭窄;普罗布考;普伐他汀

Abstract:

Keywords:

基金项目(Foundation): 山西省卫生发展项目科研基金(200230)

作者(Author): 王敬萍,安健,张悟棠,王日军,雷新宇,王仲朝,张晓娟,王慧仙,芦丽芳,李保

参考文献(References)：

• [1]Serruys PW,Luijten HE,Beatt KJ,et al.Incidence of restenosisafter successful coronary angioplasty:a time-related phenomenon.A quantitative angiographic study in 342 consecutive patients at1,2,3 and 4 months.Circulation,1988,77:361-371.
• [2]Nobuyoshi M,Kimura T,Nosaka H,et al.Restenosis after suc-cessful percutaneous transluminal coronary angioplasty:serial ang-iaographic follow-up of 299 patients.J Am Coll Cardiol,1988,12:616-623.
• [3]Cecena FA.Stenting stent:altanative strategy for treating instentrestenosis.Cathet Cardiovasc Diagn,1996,36:377-382.
• [4]Schneider JE,Berk BL,Gravanis MB,et al.Probucol decreasesneointimal formation in a swine model of coronary artery ballooninjury:a possible role for antioxidant in restenosis.Circulation,1993,88:628-637.
• [5]Rao GN,Berk BC.Active oxygen species stimulate vascularsmooth muscle cell growth and proto-oncogene expression.CircRes,1992,70:593-599.
• [6]Stiko-Rahm A,Hultgardh-Nillson A,Regnestom J,et al.Nativeand oxidized LDL enhances production of PDGF AA and the sur-face expression of PDGF receptors in cultured human smoothmuscle cells.Arterioscler Thromb,1992,12:1099-1109.
• [7]Yokoyama T,Miyauchi K,Kurata B,et al.Effect of probucol onneointimal thickening in a stent porcine restenosis model.JpnHeart J,2004,45:305-313.
• [8]Asmis R,Begley JG,Jelk J,et al.Lipoprotein aggregation protectshuman monocyte-derived macrophages from OxLDL-induced cyto-toxicity.Lipid Res,2005,46:1124-1132.
• [9]Tardif JC,C téG,Lespérance J,et al.Probucol and multivita-mins in the prevention of restenosis after coronary angioplasty.NEngl J Med,1997,337:365-372.
• [10]Deng YM,Wu BJ,Witting PK,et al.Probucol protects againstsmooth muscle cell proliferation by upregulating hemeoxygenase-1.Circulation,2004,110:1855-1860.
• [11]Wu BJ,Kathir K,Witting PK,et al.Antioxidants protect fromatherosclerosis by a heme oxygenase-1 pathway that is independ-ent of free radical scavenging.J Exp Med,2006,203:1117-1127.
• [12]Saku K,Zhang B,Jimi S,et al.Highdensity lipoprotein and apolipoprotein AⅠdeficiency induced by combination therapy withprobucol and bezafibrate.Eur J Clin Pharmacol,1995,48:209-215.
• [13]董红梅,黄岚,祝善俊,等.普罗布考对急性冠状动脉综合征患者血管内皮损伤的干预效应.中华心血管病杂志,2006,34:609-612.
• [14]Reaven PD,Parthasarathy S,Beltz WF,et al.Effect of probucoldosage on plasma lipid and lipoprotein levels and on protection oflow density lipoprotein against in vitro oxidation in humans.Arte-rioscler Thromb,1992,12:318-324.